Lancet Oncol 13(3):239246 Lingyun C (2012) Clinical analysis of adverse reactions in the application of chemotherapeutic drugs for malignant tumors
Remarkably, the fundamental question of whether to agonize or antagonize GIPR to treat obesity remains unanswered given the clinical success of both the dual GLP-1R/GIPR co-agonist tirzepatide [4] and the GIPR antagonist antibody/GLP-1R peptide agonist conjugate maridebart cafraglutide (MariTide, formerly AMG-133) [5]
Why this matters GLP-1 is on the tip of many peoples tongues because medications that act on the GLP-1 receptor produce strong effects on appetite, weight, and blood sugar
Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention
Several alternative approaches that seek to alleviate symptoms during keto-induction have been reviewed in the present work, which may help individuals and clinicians to optimize efficacy and tolerability and minimize potential adverse effects
Non-approved buyers: Complete our Online POM Form , and we will notify you once your account is Pharma approved
